Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>(rel)-MC180295

(rel)-MC180295 (Synonyms: (rel)-MC180295)

Katalog-Nr.GC34124

(rel)-MC180295 ((rel)-(rel)-MC180295) ist ein potenter und selektiver CDK9-Cyclin-T1-Inhibitor mit einem IC50 von 5 nM, mindestens 22-mal selektiver fÜr CDK9 als fÜr andere CDKs. (rel)-MC180295 hemmt auch GSK-3α und GSK-3β. (rel)-MC180295 ((rel)-(rel)-MC180295) hat eine starke Antitumorwirkung.

Products are for research use only. Not for human use. We do not sell to patients.

(rel)-MC180295 Chemische Struktur

Cas No.: 2237942-08-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
218,00 $
Auf Lager
5mg
198,00 $
Auf Lager
10mg
320,00 $
Auf Lager
50mg
1.053,00 $
Auf Lager
100mg
1.477,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(rel)-MC180295 is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. (rel)-MC180295 also inhibits GSK-3α and GSK-3β. (rel)-MC180295 has potent anti-tumor effect[1].

(rel)-MC180295 (MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs, such as CDK1-Cyclin B (IC50, 138 nM), CDK2-Cyclin A (IC50, 233 nM), CDK2-Cyclin E (IC50, 367 nM), CDK3-Cyclin E (IC50, 399 nM), CDK4-Cyclin D (IC50, 112 nM), CDK5-P35 (IC50, 159 nM), CDK5-P25 (IC50, 186 nM), CDK6-Cyclin D3 (IC50, 712 nM), and CDK7-CycH/MAT1 (IC50, 555 nM). (rel)-MC180295 also inhibits GSK-3α and GSK-3β[1].(rel)-MC180295 (500 nM) reactivates epigenetically silenced genes by targeting CDK9 without affecting DNA methylation[1].(rel)-MC180295 (0.1 μM) inhibits the proliferation in cancer cells[1].

(rel)-MC180295 (MC180295; 20 mg/kg, i.p., qod) inhibits significant anti-tumor activity in mice bearing SW48 cells, shows no inhibitory activity against human T cell growth in vivo[1].

[1]. Zhang H, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018 Nov 15;175(5):1244-1258.e26.

Bewertungen

Review for (rel)-MC180295

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (rel)-MC180295

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.